Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study

Authors: Jin Eun Choi, Sun Ha Park, Kyung Mee Kim, Won Kee Lee, Sin Kam, Sung Ick Cha, Chang Ho Kim, Young Mo Kang, Young-Chul Kim, Sung Beom Han, Tae Hoon Jung, Jae Yong Park

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Polymorphisms in Epidermal Growth Factor Receptor (EGFR) gene may influence EGFR production and/or activity, thereby modulating susceptibility to lung cancer. To test this hypothesis, we investigated the association between polymorphisms in the EGFR gene and the risk of lung cancer in a Korean population.

Methods

We first examined the frequencies of 39 candidate polymorphisms in the EGFR gene in 27 healthy Korean individuals. After then, we genotyped five polymorphisms (127378C>T, 142285G>A, 162093G>A, 181946C>T and 187114T>C) that have variant allele frequencies greater than 10%, in 582 lung cancer patients and in 582 healthy controls.

Results

Of the 5 polymorphisms, the 181946C>T genotype distribution was significantly different between the cases and controls (P = 0.04). Compared with the 181946 CC + CT genotype, the 181946 TT genotype was associated with a significantly decreased risk of lung cancer (adjusted OR = 0.63, 95% CI = 0.45–0.88, P = 0.007). When the analyses were stratified by smoking status, the protective effect of the TT genotype was statistically significant in ever-smokers (adjusted OR = 0.59, 95% CI = 0.41–0.86, P = 0.007), but not in never-smokers (adjusted OR = 0.89, 95% CI = 0.45–1.75, P = 0.73; P = 0.08, test for homogeneity). Consistent with the results of the genotyping analysis, the CGGCT haplotype with the 181946C allele was associated with a significantly increased risk of lung cancer compared to the CGGTT haplotype carrying the 181946T allele (adjusted OR = 1.50, 95% CI = 1.09–2.07, P = 0.012 and Bonferroni corrected P-value = 0.048).

Conclusion

These results suggest that the EGFR polymorphisms, particularly the 181945C>T polymorphism, could be used as markers for the genetic susceptibility to lung cancer.
Appendix
Available only for authorised users
Literature
2.
go back to reference Sekido Y, Fong KM, Minna JD: Molecular genetics of lung cancer. Ann Rev Med. 2003, 54: 73-87. 10.1146/annurev.med.54.101601.152202.CrossRefPubMed Sekido Y, Fong KM, Minna JD: Molecular genetics of lung cancer. Ann Rev Med. 2003, 54: 73-87. 10.1146/annurev.med.54.101601.152202.CrossRefPubMed
3.
go back to reference Gazdar AF, Shigematsu H, Herz J, Minna JD: Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol Med. 2004, 10: 481-486. 10.1016/j.molmed.2004.08.008.CrossRefPubMed Gazdar AF, Shigematsu H, Herz J, Minna JD: Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol Med. 2004, 10: 481-486. 10.1016/j.molmed.2004.08.008.CrossRefPubMed
4.
go back to reference Mao L: Recent advances in the molecular diagnosis of lung cancer. Oncogene. 2002, 21: 6960-6969. 10.1038/sj.onc.1205564.CrossRefPubMed Mao L: Recent advances in the molecular diagnosis of lung cancer. Oncogene. 2002, 21: 6960-6969. 10.1038/sj.onc.1205564.CrossRefPubMed
5.
go back to reference Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.CrossRefPubMed Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.CrossRefPubMed
6.
go back to reference Arteaga CL: Overview of epidermal growth factor receptor biology and its role as therapeutic target in human neoplasia. Semin Oncol. 2002, 29: 3-9.CrossRefPubMed Arteaga CL: Overview of epidermal growth factor receptor biology and its role as therapeutic target in human neoplasia. Semin Oncol. 2002, 29: 3-9.CrossRefPubMed
7.
go back to reference Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res. 2003, 284: 31-53. 10.1016/S0014-4827(02)00098-8.CrossRefPubMed Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res. 2003, 284: 31-53. 10.1016/S0014-4827(02)00098-8.CrossRefPubMed
8.
go back to reference Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004, 96: 1030-1036.CrossRefPubMed Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004, 96: 1030-1036.CrossRefPubMed
9.
go back to reference Jang JS, Lee SJ, Choi JE, et al: Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cacner. Cancer Epidemiol Biomark Prev. 2005, 14: 2474-80. 10.1158/1055-9965.EPI-05-0423.CrossRef Jang JS, Lee SJ, Choi JE, et al: Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cacner. Cancer Epidemiol Biomark Prev. 2005, 14: 2474-80. 10.1158/1055-9965.EPI-05-0423.CrossRef
10.
go back to reference Zhang X, Miao X, Guo Y, et al: Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006, 27: 110-7. 10.1002/humu.20277.CrossRefPubMed Zhang X, Miao X, Guo Y, et al: Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006, 27: 110-7. 10.1002/humu.20277.CrossRefPubMed
11.
go back to reference Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Lee JT, Park JY: Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet. 2006, 15: 1963-1971. 10.1093/hmg/ddl119.CrossRefPubMed Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Lee JT, Park JY: Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet. 2006, 15: 1963-1971. 10.1093/hmg/ddl119.CrossRefPubMed
12.
go back to reference Chrysogelos SA: Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Res. 1993, 21: 5736-5741. 10.1093/nar/21.24.5736.CrossRefPubMedPubMedCentral Chrysogelos SA: Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Res. 1993, 21: 5736-5741. 10.1093/nar/21.24.5736.CrossRefPubMedPubMedCentral
13.
go back to reference Morial T, Kobrin MS, Hope C, Speck L, Korc M: A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci USA. 1994, 91: 10217-10221. 10.1073/pnas.91.21.10217.CrossRef Morial T, Kobrin MS, Hope C, Speck L, Korc M: A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci USA. 1994, 91: 10217-10221. 10.1073/pnas.91.21.10217.CrossRef
14.
go back to reference Frederick L, Wang XY, Eley G, James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastoma. Cancer Res. 2000, 60: 1383-1387.PubMed Frederick L, Wang XY, Eley G, James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastoma. Cancer Res. 2000, 60: 1383-1387.PubMed
15.
go back to reference Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH, Ratain MJ: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005, 65: 46-53.PubMed Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH, Ratain MJ: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005, 65: 46-53.PubMed
16.
go back to reference Hsieh YY, Chang CC, Tsai FJ, Lin CC, Tsai CH: T homozygote and allele of epidermal growth factor receptor 2073 gene polymorphism are associated with higher susceptibility to endometriosis and leiomyomas. Fertility Sterility. 2005, 83: 796-799. 10.1016/j.fertnstert.2004.08.032.CrossRefPubMed Hsieh YY, Chang CC, Tsai FJ, Lin CC, Tsai CH: T homozygote and allele of epidermal growth factor receptor 2073 gene polymorphism are associated with higher susceptibility to endometriosis and leiomyomas. Fertility Sterility. 2005, 83: 796-799. 10.1016/j.fertnstert.2004.08.032.CrossRefPubMed
18.
go back to reference Park SH, Choi JE, Kim EJ, Jang JS, Lee WK, Cha SI, Kim CH, Kam S, Kim DS, Park RW, Kim YC, Han SB, Jung TH, Park JY: Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer. 2006, 54: 303-308. 10.1016/j.lungcan.2006.09.002.CrossRefPubMed Park SH, Choi JE, Kim EJ, Jang JS, Lee WK, Cha SI, Kim CH, Kam S, Kim DS, Park RW, Kim YC, Han SB, Jung TH, Park JY: Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer. 2006, 54: 303-308. 10.1016/j.lungcan.2006.09.002.CrossRefPubMed
19.
go back to reference Jun HJ, Park SH, Lee WK, Choi JE, Jang JS, Kim EJ, Cha SI, Kim DS, Kam S, Kim CH, Kang YM, Jung TH, Park JY: Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog. 2007, 46: 100-105. 10.1002/mc.20279.CrossRefPubMed Jun HJ, Park SH, Lee WK, Choi JE, Jang JS, Kim EJ, Cha SI, Kim DS, Kam S, Kim CH, Kang YM, Jung TH, Park JY: Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog. 2007, 46: 100-105. 10.1002/mc.20279.CrossRefPubMed
21.
go back to reference Stephens M, Smith MJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001, 68: 978-989. 10.1086/319501.CrossRefPubMedPubMedCentral Stephens M, Smith MJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001, 68: 978-989. 10.1086/319501.CrossRefPubMedPubMedCentral
22.
go back to reference Risch NJ: Searching for genetic determinants in the new millennium. Nature. 2000, 405: 847-856. 10.1038/35015718.CrossRefPubMed Risch NJ: Searching for genetic determinants in the new millennium. Nature. 2000, 405: 847-856. 10.1038/35015718.CrossRefPubMed
23.
go back to reference Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how cancer we measure it?. Carcinog. 2002, 23: 381-387. 10.1093/carcin/23.3.381.CrossRef Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how cancer we measure it?. Carcinog. 2002, 23: 381-387. 10.1093/carcin/23.3.381.CrossRef
24.
go back to reference Becker N, Nieters A, Rittgen W: Single nucleotide polymorphism-disease relationship: statistical issues for the performance of association studies. Mut Res. 2003, 525: 11-18.CrossRef Becker N, Nieters A, Rittgen W: Single nucleotide polymorphism-disease relationship: statistical issues for the performance of association studies. Mut Res. 2003, 525: 11-18.CrossRef
25.
go back to reference Kang D, Gridley G, Huang WY, Engel LS, Winn DM, Brown LM, Bravo-Otero E, Wu T, Diehl SR, Hayes RB: Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor- (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet Genomics. 2005, 15: 343-347.CrossRefPubMed Kang D, Gridley G, Huang WY, Engel LS, Winn DM, Brown LM, Bravo-Otero E, Wu T, Diehl SR, Hayes RB: Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor- (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet Genomics. 2005, 15: 343-347.CrossRefPubMed
26.
go back to reference Lee SJ, Kim KM, Chae MH, Lee WK, Kam S, Cha SI, Han HS, Kim CH, Kang YM, Han SB, Park JY: No association between dinucleotide repeats polymorphism in intron 1 of the epidermal growth factor receptor gene EGFR and risk of lung cancer. Cancer Genet Cytogenet. 2007, 172: 29-32. 10.1016/j.cancergencyto.2006.07.012.CrossRefPubMed Lee SJ, Kim KM, Chae MH, Lee WK, Kam S, Cha SI, Han HS, Kim CH, Kang YM, Han SB, Park JY: No association between dinucleotide repeats polymorphism in intron 1 of the epidermal growth factor receptor gene EGFR and risk of lung cancer. Cancer Genet Cytogenet. 2007, 172: 29-32. 10.1016/j.cancergencyto.2006.07.012.CrossRefPubMed
27.
go back to reference Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, Kaloshi G, Delattre JY, Thillet J, Sanson M: Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology. 2006, 67: 872-874. 10.1212/01.wnl.0000229927.12007.37.CrossRefPubMed Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, Kaloshi G, Delattre JY, Thillet J, Sanson M: Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology. 2006, 67: 872-874. 10.1212/01.wnl.0000229927.12007.37.CrossRefPubMed
28.
go back to reference Gebhard F, Zanker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999, 274: 13176-13180. 10.1074/jbc.274.19.13176.CrossRef Gebhard F, Zanker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999, 274: 13176-13180. 10.1074/jbc.274.19.13176.CrossRef
29.
go back to reference Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-onahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitor. Cancer Res. 2004, 64: 9139-9143. 10.1158/0008-5472.CAN-04-1036.CrossRefPubMed Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-onahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitor. Cancer Res. 2004, 64: 9139-9143. 10.1158/0008-5472.CAN-04-1036.CrossRefPubMed
30.
go back to reference Bader JS: The relative power of SNPs and haplotypes as genetic markers for association tests. Pharmaocogenomics. 2001, 2: 11-24. 10.1517/14622416.2.1.11.CrossRef Bader JS: The relative power of SNPs and haplotypes as genetic markers for association tests. Pharmaocogenomics. 2001, 2: 11-24. 10.1517/14622416.2.1.11.CrossRef
31.
go back to reference Judson R, Stephens JC, Windemuth A: The predictive power of haplotypes in clinical response. Pharmacogenomics. 2000, 1: 15-26. 10.1517/14622416.1.1.15.CrossRefPubMed Judson R, Stephens JC, Windemuth A: The predictive power of haplotypes in clinical response. Pharmacogenomics. 2000, 1: 15-26. 10.1517/14622416.1.1.15.CrossRefPubMed
32.
go back to reference Judson R, Stephens JC: Notes from the SNP vs. haplotype front. Pharmacogenomics. 2001, 2: 7-10. 10.1517/14622416.2.1.7.CrossRefPubMed Judson R, Stephens JC: Notes from the SNP vs. haplotype front. Pharmacogenomics. 2001, 2: 7-10. 10.1517/14622416.2.1.7.CrossRefPubMed
33.
go back to reference Hoh J, Hodge S: A measure of phase ambiguity in pairs of SNPs in the presence of linkage disequilibrium. Hum Hered. 2000, 50: 359-364. 10.1159/000022941.CrossRefPubMed Hoh J, Hodge S: A measure of phase ambiguity in pairs of SNPs in the presence of linkage disequilibrium. Hum Hered. 2000, 50: 359-364. 10.1159/000022941.CrossRefPubMed
34.
go back to reference Xu CF, Lewis K, Cantone KL, Khan P, Donnelly C, White N, Crocker N, Boyd PR, Zaykin DV, Purvis IJ: Effectiveness of computational methods in haplotype estimation. Hum Genet. 2002, 110: 148-156. 10.1007/s00439-001-0656-4.CrossRefPubMed Xu CF, Lewis K, Cantone KL, Khan P, Donnelly C, White N, Crocker N, Boyd PR, Zaykin DV, Purvis IJ: Effectiveness of computational methods in haplotype estimation. Hum Genet. 2002, 110: 148-156. 10.1007/s00439-001-0656-4.CrossRefPubMed
Metadata
Title
Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study
Authors
Jin Eun Choi
Sun Ha Park
Kyung Mee Kim
Won Kee Lee
Sin Kam
Sung Ick Cha
Chang Ho Kim
Young Mo Kang
Young-Chul Kim
Sung Beom Han
Tae Hoon Jung
Jae Yong Park
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-199

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine